155 related articles for article (PubMed ID: 36115922)
41. Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.
Ceresoli GL; Grosso F; Zucali PA; Mencoboni M; Pasello G; Ripa C; Degiovanni D; Simonelli M; Bruzzone A; Dipietrantonj C; Piccolini E; Beretta GD; Favaretto AG; Giordano L; Santoro A; Botta M
Br J Cancer; 2014 Jul; 111(2):220-6. PubMed ID: 24918816
[TBL] [Abstract][Full Text] [Related]
42. Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis.
Mosleh B; Schelch K; Mohr T; Klikovits T; Wagner C; Ratzinger L; Dong Y; Sinn K; Ries A; Berger W; Grasl-Kraupp B; Hoetzenecker K; Laszlo V; Dome B; Hegedus B; Jakopovic M; Hoda MA; Grusch M
Thorac Cancer; 2023 Aug; 14(22):2177-2186. PubMed ID: 37340889
[TBL] [Abstract][Full Text] [Related]
43. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
[TBL] [Abstract][Full Text] [Related]
44. The recurrence of malignant pleural mesothelioma 14 years after extrapleural pneumonectomy: possible histological transformation.
Kinoshita T; Ishii G; Matsumura Y; Shiozawa T; Aokage K; Hishida T; Yoshida J; Nagai K
Pathol Int; 2012 Nov; 62(11):754-7. PubMed ID: 23121607
[TBL] [Abstract][Full Text] [Related]
45. Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Grover S; Friedberg JS; Simone CB
J Thorac Cardiovasc Surg; 2019 Feb; 157(2):758-766.e1. PubMed ID: 30454981
[TBL] [Abstract][Full Text] [Related]
46. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
Deraco M; Cabras A; Baratti D; Kusamura S
Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091
[TBL] [Abstract][Full Text] [Related]
47. The prognostic analysis of the some clinicopathological parameters and gene protein expressions in malignant mesothelioma.
Tohumcuoğlu M; Büyükşimşek M; Kara İO; Gümürdülü D; Bağır E
Tuberk Toraks; 2019 Sep; 67(3):162-168. PubMed ID: 31709947
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort.
Cedres S; Assaf JD; Iranzo P; Callejo A; Pardo N; Navarro A; Martinez-Marti A; Marmolejo D; Rezqallah A; Carbonell C; Frigola J; Amat R; Pedrola A; Dienstmann R; Felip E
Sci Rep; 2021 Nov; 11(1):21357. PubMed ID: 34725384
[TBL] [Abstract][Full Text] [Related]
49. Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies.
Habougit C; Trombert-Paviot B; Karpathiou G; Casteillo F; Bayle-Bleuez S; Fournel P; Vergnon JM; Tiffet O; Péoc'h M; Forest F
Virchows Arch; 2017 Jun; 470(6):639-646. PubMed ID: 28349237
[TBL] [Abstract][Full Text] [Related]
50. Multimodality Therapy in Patients With Primary Pericardial Mesothelioma.
Offin M; De Silva DL; Sauter JL; Egger JV; Yorke E; Adusumilli PS; Rimner A; Rusch VW; Zauderer MG
J Thorac Oncol; 2022 Dec; 17(12):1428-1432. PubMed ID: 36075530
[TBL] [Abstract][Full Text] [Related]
51. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
Inaguma S; Lasota J; Wang Z; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Miettinen M
Hum Pathol; 2018 Jan; 71():1-7. PubMed ID: 28811252
[TBL] [Abstract][Full Text] [Related]
52. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T
Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615
[TBL] [Abstract][Full Text] [Related]
53. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
[TBL] [Abstract][Full Text] [Related]
54. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S
Tumori; 2016; 102(2):190-5. PubMed ID: 26893272
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
[TBL] [Abstract][Full Text] [Related]
56. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
[TBL] [Abstract][Full Text] [Related]
57. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.
Rosen LE; Karrison T; Ananthanarayanan V; Gallan AJ; Adusumilli PS; Alchami FS; Attanoos R; Brcic L; Butnor KJ; Galateau-Sallé F; Hiroshima K; Kadota K; Klampatsa A; Stang NL; Lindenmann J; Litzky LA; Marchevsky A; Medeiros F; Montero MA; Moore DA; Nabeshima K; Pavlisko EN; Roggli VL; Sauter JL; Sharma A; Sheaff M; Travis WD; Vigneswaran WT; Vrugt B; Walts AE; Tjota MY; Krausz T; Husain AN
Mod Pathol; 2018 Apr; 31(4):598-606. PubMed ID: 29327706
[TBL] [Abstract][Full Text] [Related]
58. The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.
Chou A; Toon CW; Clarkson A; Sheen A; Sioson L; Gill AJ
Histopathology; 2018 Feb; 72(3):509-515. PubMed ID: 28889523
[TBL] [Abstract][Full Text] [Related]
59. Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
Paajanen J; Laaksonen S; Ilonen I; Wolff H; Husgafvel-Pursiainen K; Kuosma E; Ollila H; Myllärniemi M; Vehmas T
Lung Cancer; 2018 Feb; 116():73-79. PubMed ID: 29413055
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.
Chirieac LR; Hung YP; Foo WC; Hofer MD; VanderLaan PA; Richards WG; Sugarbaker DJ; Bueno R
Cancer; 2019 Dec; 125(23):4164-4171. PubMed ID: 31390057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]